| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
BIOA
BioAge Labs, Inc.
|
Aug 06, 2026 | BUY |
Strong Buy
+226.7% avg upside
9 analysts
|
$35.00
210.58% Upside
|
· | · |
|
ANNX
Annexon Biosciences
|
Aug 06, 2026 | BUY |
Strong Buy
+153.1% avg upside
14 analysts
|
$25.00
346.49% Upside
|
· | · |
|
PCVX
Vaxcyte
|
Aug 06, 2026 | BUY |
Strong Buy
+71.6% avg upside
15 analysts
|
$110.00
86.80% Upside
|
+0.0% | · |
|
VIR
Vir Biotechnology
|
Aug 06, 2026 | BUY |
Strong Buy
+191.6% avg upside
16 analysts
|
$18.00
105.34% Upside
|
· | · |
|
GILD
Gilead Sciences
|
Aug 05, 2026 | BUY |
Strong Buy
-9.1% avg upside
66 analysts
|
$170.00
29.90% Upside
|
+1.1% | · |
|
VRTX
Vertex Pharmaceuticals
|
Aug 04, 2026 | HOLD |
Strong Buy
-8.3% avg upside
62 analysts
|
— | +1.3% | · |
|
STOK
Stoke Therapeutics
|
Aug 04, 2026 | BUY |
Strong Buy
+25.1% avg upside
18 analysts
|
$40.00
25.19% Upside
|
+1.2% | · |
|
RYTM
Rhythm Pharmaceuticals
|
Aug 04, 2026 | BUY |
Strong Buy
+10.7% avg upside
19 analysts
|
$130.00
16.04% Upside
|
· | · |
|
MRNA
Moderna
|
Jul 31, 2026 | HOLD |
Hold
+30.6% avg upside
38 analysts
|
— | +7.9% | · |
|
PHAT
Phathom Pharmaceuticals
|
Jul 30, 2026 | BUY |
Strong Buy
+216.3% avg upside
14 analysts
|
$22.00
162.22% Upside
|
-5.3% | · |
|
ALNY
Alnylam Pharma
|
Jul 30, 2026 | BUY |
Strong Buy
+47.8% avg upside
51 analysts
|
$357.00
65.22% Upside
|
+4.7% | · |
|
IONS
Ionis Pharmaceuticals
|
Jul 29, 2026 | BUY |
Strong Buy
+45.6% avg upside
43 analysts
|
$86.00
57.78% Upside
|
+4.7% | · |
|
STTK
Shattuck Labs
|
Jun 08, 2026 | BUY |
Strong Buy
+205.1% avg upside
15 analysts
|
$17.00
137.38% Upside
|
+83.6% | · |
|
PLRX
Pliant Therapeutics
|
May 12, 2026 | HOLD |
Buy
+2022.0% avg upside
21 analysts
|
— | -11.9% | · |
|
LXRX
Lexicon Pharmaceuticals
|
Apr 21, 2025 | HOLD |
Buy
+68.9% avg upside
9 analysts
|
— | +6937.0% | · |
|
TVRD
Tvardi Therapeutics
|
Aug 16, 2024 | HOLD |
Strong Buy
+864.4% avg upside
23 analysts
|
— | +99.0% | · |
|
TBPH
Theravance Biopharma
|
Dec 23, 2022 | HOLD |
Buy
+9.0% avg upside
18 analysts
|
— | -2.3% | · |
|
ACAD
ACADIA Pharmaceuticals
|
Aug 05, 2021 | BUY |
Strong Buy
+27.8% avg upside
43 analysts
|
$26.00
8.61% Downside
|
-14.6% | · |
|
NBIX
Neurocrine
|
Aug 04, 2021 | HOLD |
Strong Buy
+16.8% avg upside
37 analysts
|
— | +2.9% | · |
|
CRSP
Crispr Therapeutics AG
|
Apr 28, 2021 | BUY |
Buy
+47.4% avg upside
41 analysts
|
$170.00
229.25% Upside
|
-61.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.